Published July 23, 2026
The Suboxone tooth decay litigation that today includes thousands of claims against Indivior traces back to a single procedural order in February 2024. On February 2, 2024, the U.S. Judicial Panel on Multidistrict Litigation issued a transfer order consolidating federal lawsuits over Suboxone film's dental effects into a new multidistrict litigation, MDL No. 3092, centralized before U.S. District Judge J. Philip Calabrese in the Northern District of Ohio. More than 20 lawsuits were transferred into the new MDL at the outset, with the expectation that many more "tag-along" cases would follow as they were filed.
Suboxone film is a strip form of buprenorphine and naloxone, prescribed to treat opioid use disorder, that dissolves under the tongue or against the inside of the cheek. The lawsuits allege that Indivior and its former parent company knew or should have known that prolonged, repeated contact between the dissolving film and tooth enamel could cause serious dental injuries — including tooth decay, cavities, tooth fractures, and tooth loss — and failed to adequately warn patients or prescribers. The FDA required an updated warning about these dental risks be added to Suboxone's label in 2022, after receiving a wave of adverse event reports, and that label change became a key reference point for when the manufacturer should have known about the risk.
Consolidating the cases into a single MDL rather than leaving them scattered across federal courts nationwide let the litigation move through shared discovery, a unified case management structure, and coordinated bellwether case selection — all under one judge. That structure is what has allowed the litigation to scale: from a starting group of roughly 20 transferred cases in February 2024 to a docket that, by mid-2026, includes more than 17,900 individual claims against Indivior.
Every case management order, discovery deadline, and bellwether selection process now shaping the litigation flows from the structure the JPML put in place at formation. Understanding that this is a relatively young MDL — still in the discovery and bellwether-selection phase, with a first trial not expected before 2028 — helps set realistic expectations for anyone considering a claim today: this is very much an active, developing case rather than one nearing a resolution.
If you or a family member used Suboxone film and later experienced significant dental damage, it's worth getting your eligibility reviewed regardless of how early the litigation still is — state filing deadlines don't wait for the MDL to mature. See Atumio's Suboxone case page for a free review, or start your case review directly.